Market News

Iguana Healthcare Management Has Decreased Its Medicines Co (MDCO) Stake as Stock Declined; Freeport (FCX) Shareholder Icahn Carl C Has Cut Holding as Valuation Declined

Carl Icahn decreased its stake in Freeport (FCX) by 15.76% based on its latest 2017Q3 regulatory filing with the SEC. Icahn Carl C sold 14.43 million shares as the company’s stock declined 21.33% while stock markets rallied. The hedge fund run by Carl Icahn held 77.16M shares of the basic industries company at the end of 2017Q3, valued at $1.08 billion, down from 91.59M at the end of the previous reported quarter. Icahn Carl C who had been investing in Freeport for a number of months, seems to be less bullish one the $27.11B market cap company. The stock decreased 2.04% or $0.39 during the last trading session, reaching $18.73. About 16.55 million shares traded. Freeport-McMoRan Inc. (NYSE:FCX) has risen 6.83% since February 17, 2017 and is uptrending. It has underperformed by 9.87% the S&P500.

Stuart Weisbrod decreased its stake in Medicines Co (MDCO) by 33.33% based on its latest 2017Q3 regulatory filing with the SEC. Iguana Healthcare Management Llc sold 50,000 shares as the company’s stock declined 20.30% while stock markets rallied. The hedge fund run by Stuart Weisbrod held 100,000 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $3.70M, down from 150,000 at the end of the previous reported quarter. Iguana Healthcare Management Llc who had been investing in Medicines Co for a number of months, seems to be less bullish one the $2.39B market cap company. The stock increased 2.54% or $0.82 during the last trading session, reaching $33.16. About 1.84 million shares traded or 26.56% up from the average. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since February 17, 2017 and is uptrending. It has by 0.00% the S&P500.

Investors sentiment is 1 in 2017 Q3. Its the same as in 2017Q2. It is without change, as 57 investors sold FCX shares while 214 reduced holdings. only 91 funds opened positions while 181 raised stakes. 961.13 million shares or 0.14% less from 962.50 million shares in 2017Q2 were reported. Walleye Trading Ltd Company stated it has 686,217 shares. Metropolitan Life Insurance owns 648,811 shares. National Bank & Trust Of Montreal Can reported 846,100 shares. Moreover, Hyman Charles D has 0.12% invested in Freeport-McMoRan Inc. (NYSE:FCX) for 70,325 shares. Nippon Life Insurance Com reported 61,463 shares. Meyer Handelman owns 0.37% invested in Freeport-McMoRan Inc. (NYSE:FCX) for 569,503 shares. Parkside Bankshares And reported 2,874 shares or 0.02% of all its holdings. Alps Advsrs Inc, a Colorado-based fund reported 22,093 shares. Cap Glob Investors reported 91.82 million shares. Stratos Wealth Ptnrs Limited holds 42,666 shares or 0.03% of its portfolio. Moreover, Marshwinds Advisory Comm has 0.09% invested in Freeport-McMoRan Inc. (NYSE:FCX) for 13,775 shares. 192,100 were reported by Jupiter Asset Mgmt Ltd. Toronto Dominion National Bank holds 0.02% or 519,957 shares. Rand Wealth Llc has 13,925 shares for 0.02% of their portfolio. 177,945 were accumulated by Essex Investment Mgmt Limited Co.

Since August 21, 2017, it had 0 insider purchases, and 1 insider sale for $419,125 activity.

Among 23 analysts covering Freeport-McMoran Copper & Gold (NYSE:FCX), 4 have Buy rating, 5 Sell and 14 Hold. Therefore 17% are positive. Freeport-McMoran Copper & Gold had 97 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Wednesday, June 28. The stock has “Outperform” rating by Cowen & Co on Friday, July 24. The company was maintained on Tuesday, July 18 by Stifel Nicolaus. BMO Capital Markets maintained the stock with “Hold” rating in Monday, August 28 report. The stock of Freeport-McMoRan Inc. (NYSE:FCX) has “Outperform” rating given on Monday, May 16 by Cowen & Co. The company was upgraded on Monday, December 11 by Morgan Stanley. Deutsche Bank maintained Freeport-McMoRan Inc. (NYSE:FCX) rating on Monday, August 31. Deutsche Bank has “Buy” rating and $17 target. The rating was maintained by FBR Capital with “Mkt Perform” on Friday, February 3. The stock of Freeport-McMoRan Inc. (NYSE:FCX) has “Hold” rating given on Wednesday, March 22 by Berenberg. The stock of Freeport-McMoRan Inc. (NYSE:FCX) earned “Hold” rating by RBC Capital Markets on Sunday, December 3.

Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.44, from 1.22 in 2017Q2. It worsened, as 32 investors sold MDCO shares while 64 reduced holdings. 19 funds opened positions while 56 raised stakes. 85.15 million shares or 1.36% less from 86.33 million shares in 2017Q2 were reported. Ny State Teachers Retirement invested in 0.01% or 147,007 shares. Whittier Of Nevada holds 1,037 shares or 0% of its portfolio. Manufacturers Life Insur The owns 52,511 shares or 0% of their US portfolio. Landscape Capital Mgmt Limited Liability Company invested in 12,732 shares or 0.05% of the stock. Stoneridge Inv Prns Ltd Liability Company owns 25,351 shares. Jpmorgan Chase & owns 0% invested in The Medicines Company (NASDAQ:MDCO) for 257,234 shares. Glob X Management Co Limited Co holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 482 shares. Proshare Advsrs Limited Com reported 48,424 shares. Price T Rowe Assoc Inc Md holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 320,023 shares. Quantbot Technologies Limited Partnership accumulated 4,622 shares or 0.02% of the stock. Prudential Inc owns 108,442 shares for 0.01% of their portfolio. 58,651 are held by Mutual Of America Mngmt Ltd Liability Corporation. Geode Capital Mgmt Limited Company owns 633,031 shares for 0.01% of their portfolio. Tennessee-based State Of Tennessee Treasury Department has invested 0.01% in The Medicines Company (NASDAQ:MDCO). California Pub Employees Retirement holds 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 159,600 shares.

Since December 7, 2017, it had 1 insider buy, and 1 insider sale for $1.60 million activity. 200,000 shares were bought by ESHELMAN FREDRIC N, worth $5.31 million on Thursday, December 7.

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The Medicines Co had 35 analyst reports since August 28, 2015 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Buy” on Monday, August 31. H.C. Wainwright maintained The Medicines Company (NASDAQ:MDCO) rating on Tuesday, July 25. H.C. Wainwright has “Buy” rating and $6000 target. H.C. Wainwright initiated it with “Buy” rating and $57 target in Monday, December 5 report. On Monday, January 15 the stock rating was maintained by Oppenheimer with “Buy”. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Tuesday, September 12 by Jefferies. On Monday, July 17 the stock rating was maintained by Citigroup with “Neutral”. Jefferies maintained The Medicines Company (NASDAQ:MDCO) rating on Wednesday, August 2. Jefferies has “Buy” rating and $6200 target. The stock of The Medicines Company (NASDAQ:MDCO) has “Outperform” rating given on Monday, November 16 by RBC Capital Markets. The stock of The Medicines Company (NASDAQ:MDCO) has “Market Perform” rating given on Monday, August 31 by Oppenheimer. Citigroup maintained it with “Neutral” rating and $44 target in Monday, August 14 report.

Leave a Reply

Your email address will not be published. Required fields are marked *